CPT® Code 88275

The CPT® Code 88275 refers to a laboratory test that focuses on molecular cytogenetics through the technique of interphase in situ hybridization. This procedure is designed to analyze a sample of 100 to 300 cells, which can be derived from various biological sources such as bone marrow, blood, amniotic fluid, chorionic villi, and other body tissues or tumors. Molecular cytogenetics is a branch of genetics that studies the structure and function of chromosomes, including their abnormalities and variations within the genome. The interphase in situ hybridization method, specifically interphase fluorescence in situ hybridization (I-FISH), allows for the examination of the nuclei of eukaryotic cells, providing insights into a wider range of cell types. Samples for this test are typically obtained through procedures that are reported separately, including venipuncture, bone marrow aspiration, amniocentesis, chorionic villus sampling, and biopsy. The analysis performed using this code is crucial for rapid detection of chromosomal aneuploidies, particularly for chromosomes X, Y, 13, 18, and 21, in maternal amniotic fluid or chorionic villi, as well as in whole blood from infants. Additionally, this test plays a significant role in the risk stratification of patients with newly diagnosed or relapsed multiple myeloma, the detection of genomic abnormalities in chronic lymphocytic leukemia, and the diagnosis and classification of hematopoietic neoplasms presenting with eosinophilia. Furthermore, the examination of blood and bone marrow samples can support the diagnosis of acute lymphocytic leukemia and confirm the presence of PML-RARA translocation in acute promyelocytic leukemia. It is also utilized to exclude cryptic BCR-ABL1 rearrangements in myelogenous leukemia patients or PDGFRA abnormalities in those with neoplastic eosinophilia. The test is instrumental in diagnosing and predicting aggressive morphologic features in cases of Burkitt lymphoma versus diffuse large B-cell lymphoma, as well as monitoring minimal residual disease in therapy-related myelodysplastic syndrome (MDS) or acute myelogenous leukemia associated with MDS. Lastly, whole blood samples may be analyzed to identify significant translocations in patients newly diagnosed with acute myeloid leukemia. It is important to note that CPT® Code 88274 is applicable when analyzing 25-99 cells, while CPT® Code 88275 is specifically designated for the analysis of 100-300 cells.